(Q51965010)

19 April 2018

title

Long-term increase of CD4+ central memory cells in HIV-1-infected individuals by therapeutic HIV-1 rgp160 immunization. (English)

1 reference

19 April 2018

author

Nesrina Imami

8

1 reference

19 April 2018

Lindvi Gudmundsdotter

1

object named as

Lindvi Gudmundsdotter

1 reference

19 April 2018

Britta Wahren

7

object named as

Britta Wahren

1 reference

19 April 2018

author name string

Ann-Charlotte Boström

2

1 reference

19 April 2018

Catherine Burton

3

1 reference

19 April 2018

Guglielmo Rosignoli

4

1 reference

19 April 2018

Eric Sandström

5

1 reference

19 April 2018

Bo Hejdeman

6

1 reference

19 April 2018

Frances Gotch

9

1 reference

19 April 2018

language of work or name

English

0 references

publication date

14 April 2008

1 reference

19 April 2018

published in

Vaccine

1 reference

19 April 2018

volume

26

1 reference

19 April 2018

issue

40

1 reference

19 April 2018

page(s)

5107-5110

1 reference

19 April 2018

Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.063

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.063

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.063

Cellular immune responses to HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.063

Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.063

HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.063

CD4+ lymphocyte function with early human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.063

Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.063

Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.063

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.063

Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.063

HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.063

Skewed maturation of memory HIV-specific CD8 T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.063

Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.063

Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.063

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.063

Induction of specific T-cell responses in HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.063

A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.063

Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.063

Better preserved immune responses after immunization with rgp 160 in HIV-1 infected patients treated with highly active antiretroviral therapy than in untreated patients with similar CD4 levels during at 2 years' follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.063

HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.063

Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.063

10.1016/J.VACCINE.2008.03.063

7 January 2021

Identifiers

DOI

1 reference

19 April 2018

1 reference

19 April 2018